Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KUR 502

Next Previous
Drug Profile

KUR 502

Alternative Names: CAR-NKT therapy - Athenex; CD19-CAR-aNKT cells - Athenex; CD19.CAR-aNKT cells - Athenex; CMD-502; KUR-502

Latest Information Update: 16 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine
  • Developer Athenex; Baylor College of Medicine; Kuur Therapeutics
  • Class Antineoplastics; CAR-NK cell therapies; CAR-T cell therapies; Gene therapies; Immunotherapies; NKT cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Interleukin 15 replacements; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 12 Sep 2023 Discontinued - Phase-I for Chronic lymphocytic leukaemia (In children, In the elderly, Second-line therapy or greater, In adults) in USA (IV)
  • 12 Sep 2023 Discontinued - Phase-I for Non-Hodgkin's lymphoma (In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in USA (IV)
  • 12 Sep 2023 Discontinued - Phase-I for Precursor cell lymphoblastic leukaemia-lymphoma (In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top